Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479207 | 0.89 | PPARD (0.58) | PPARDTSHRALDH1A1CYP1A2MEN1 | |
| Oxalic Acid SCHEMBL3175186 | 0.88 | PPARD (0.50) | PPARDTSHRCYP1A2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11686519 | 0.87 | PPARD (0.56) | PPARDTSHRALDH1A1CYP1A2MEN1 | |
| Oxalic Acid SCHEMBL5022542 | 0.86 | PPARD (0.48) | PPARDTSHRCYP1A2MEN1KMT2A | |
| Oxalic Acid SCHEMBL282616 | 0.83 | TSHR (0.48) | PPARDTSHRMEN1KMT2ATP53 | |
| Oxalic Acid SCHEMBL27997610 | 0.83 | TSHR (0.48) | PPARDTSHRMEN1KMT2ATP53 | |
| Oxalic Acid SCHEMBL28201642 | 0.80 | TSHR (0.37) | PPARDTSHRALDH1A1CYP1A2MEN1 | |
| SCHEMBL27711689 | 0.78 | TSHR (0.48) | PPARDTSHRALDH1A1CYP1A2MEN1 | |
| Oxalic Acid SCHEMBL3483591 | 0.78 | TSHR (0.60) | PPARDTSHRTP53TDP1MAPT | |
| SCHEMBL491488 | 0.76 | PPARD (0.54) | PPARDTSHRCYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| US-9827258-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2017-08-24 | — | — | US | disclosed |
| US-9572824-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. | 2016-05-12 | — | — | US | disclosed |
| US-9186367-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BOIGEN MA INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2461683-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2015-04-29 | — | — | EP | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005044308-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005039552-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS AS PHOSPHONATE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | PPARD 1325/4885TSHR 165/4885ALDH1A1 4545/4885 |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | PPARD 915/4885TSHR 452/4885ALDH1A1 3931/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | PPARD 1134/4885TSHR 4304/4885ALDH1A1 3720/4885 |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | PPARD 1325/4885TSHR 165/4885ALDH1A1 4545/4885 |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | PPARD 1325/4885TSHR 165/4885ALDH1A1 4545/4885 |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | IMPDH1, IMPDH2, ITPA | PPARD 2303/4885TSHR 4058/4885ALDH1A1 312/4885 |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | PPARD 915/4885TSHR 452/4885ALDH1A1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.